VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | Omitting total lymph node dissection and adjuvant therapy in melanoma

Following the results from the Phase II OpACIN-neo trial (NCT02977052) assessing ipilimumab and nivolumab in melanoma, pathologic response rate was correlated to two-year survival rates. Irene Reijers, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes the trial design and rationale of the following Phase II PRADO trial (NCT02977052), where patients with stage III melanoma therapeutic were given neoadjuvant ipilimumab and nivolumab. Patients who have achieved a major pathologic response in the index lymph node received follow-up, whereas patients with no response received a total lymph node dissection and adjuvant nivolumab or dabrafenib plus trametinib. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter